市場調查報告書
商品編碼
1563126
全球放射腫瘤學市場:依類型、應用、最終用戶和地區的預測(~2032年)Global Radiation Oncology Market Research Report Information by Type, By Application, By End-User And by Region -Forecast Till 2032 |
放射腫瘤學市場規模將從2023年的82.3億美元成長到2024年的89億美元,預測期內年複合成長率為 8.0%,預計到2032年將成長到 165.1億美元。全球癌症發生率的上升以及聯合療法(包括除手術和化療外的放射腫瘤學)的接受度不斷提高,推動市場擴張。
人口老化、生活方式改變和環境因素導致全球癌症發生率增加是市場的主要驅動力。調強放射治療(IMRT)、立體定位放射外科(SRS)和質子治療等放射治療技術進步顯著提高了治療準確性和患者治療效果,推動了市場成長。此外,日益使用聯合療法,包括化療和手術之外的放射腫瘤學,也透過為患者提供更全面和有效的治療選擇來促進市場擴張。
癌症發生率的上升也是放射性腫瘤快速成長的主要動力。由於癌症發病率上升,全球對有效替代療法的需求不斷成長,因此市場日益擴大。
區域洞察
北美地區在2023年佔據最高市場佔有率,預計到2032年將達到約 72.4億美元,預測期內年複合成長率為 8.2%。同時,亞太地區預計在預測期內將以8.4%的最高年複合成長率發展。
由於許多地區特定因素,北美放射腫瘤市場迅速擴大。北美癌症發生率的增加是一個重要的決定因素。隨著生活方式的改變和老化導致癌症發生率增加,對放射腫瘤服務的需求也會增加。
在許多地區特定因素的推動下,歐洲放射腫瘤市場可望顯著成長。整個歐洲癌症發生率的上升是一個重要的決定因素。癌症發生率上升增加了對放射治療等先進治療技術的需求。
在各種地區特定原因的推動下,亞太地區的放射腫瘤市場預計將顯著成長。亞太地區癌症盛行率不斷上升是重要因素。
本報告調查了全球放射腫瘤學市場,提供市場的定義和概述,市場成長的各種影響因素分析,市場規模推移和預測,各種區分、地區的細分,競爭環境,主要企業概況等彙整資料。
Global Radiation Oncology Market Research Report Information by Type (External Beam Radiation Therapy and Internal Radiation Therapy), By Application (Prostate Cancer, Breast Cancer, Lung Cancer, Head & Neck, and Others), By End-User (Hospitals & Clinics, Oncology Centers and Academic & Research Institutes) And by Region (North America, Europe, Asia-Pacific, and Rest of The World) -Forecast Till 2032
In 2023, the Radiation Oncology Market was valued at USD 8.23 billion. The market is expected to expand from USD 8.90 billion in 2024 to USD 16.51 billion by 2032, with a compound annual growth rate (CAGR) of 8.0% over the forecast period (2024-2032). The rising prevalence of cancer worldwide, as well as the growing acceptance of combination therapies that include radiation oncology in addition to surgery and chemotherapy, are driving market expansion.
The increased global prevalence of cancer, driven by aging populations, lifestyle changes, and environmental factors, is the primary driver of the radiation oncology industry. Technological advances in radiation therapy, including as intensity-modulated radiation therapy (IMRT), stereotactic radiosurgery (SRS), and proton therapy, have significantly improved treatment accuracy and patient outcomes, driving market growth. Furthermore, the growing use of combination therapies that include radiation oncology in addition to chemotherapy and surgery helps to expand the market by giving patients with more comprehensive and productive treatment options.
The rising incidence of cancer has emerged as a major impetus for the rapid growth of radiation oncology. The radiation oncology market is expanding as a result of rising global demand for effective treatment alternatives in response to cancer's increasing prevalence.
Market Segment insights
The Radiation Oncology Market is divided into two product types: external beam radiation therapy and internal beam radiation therapy.
The Radiation Oncology Market has been segmented by price range into Prostate Cancer, Breast Cancer, Lung Cancer, Head and Neck Cancer, and Others.
The market has been divided into three segments based on the end user: hospitals and clinics, oncology centers, and academic and research institutions.
Regional insights
The Radiation Oncology Market has been classified by region: North America, Europe, Asia-Pacific, and the Rest of the World. North America held the highest market share in 2023 and is expected to reach roughly USD 7.24 billion by 2032, growing at an 8.2% CAGR over the forecast period. However, Asia-Pacific is expected to develop at the fastest CAGR of 8.4% over the projection period.
The radiation oncology market in North America is rapidly expanding, driven by a number of unique regional variables. The increased incidence of cancer in North America is a key determinant. As cancer incidence rises due to lifestyle changes and an aging population, so does the demand for radiation oncology services.
The radiation oncology market in Europe is poised for significant growth, driven by a number of regionally specific reasons. The increased cancer incidence across Europe is a key determinant. The increasing prevalence of cancer has created a greater demand for sophisticated therapeutic techniques, such as radiation therapy.
The radiation oncology market in the Asia Pacific area is expected to grow significantly, driven by a variety of region-specific reasons. The increasing prevalence of cancer in the Asia-Pacific area is a significant factor.
Varian Medical Systems, Inc. (US), Elekta (Sweden), Accuracy Incorporated (US), IBA Radiopharma Solutions (Belgium), BD (US), Mevion Medical Systems (US), Nordion (Canada), NTP Radioisotopes Soc Ltd. (South Africa), Curium (France), and Reflexion (US) are among the key players in the Radiation Oncology Market.